Prostate Specific Antigen

Prostate Specific Antigen - most related articles:

- Prostate biopsy is not always necessary after raised PSA levels - 8.1
- STD increases prostate cancer risk - 7
- Prostate cancer screening for men over 75 not required - 6.2
- PSA test helps predicting biopsy need and low risk prostate cancer - 6.1
- Genetic testing can gauge prostate cancer risk - 6
- Brothers of prostate cancer patients undergo more diagnostic activities - 5.8
- More aggressive treatment not necessary for men with a family history of prostate cancer - 5.7
- Prostate cancer screening may result in overdiagnosis of cancer - 5.6
- Prostate cancer test age lowered to 40 - 5.6
- Green tea slows prostate cancer progression - 5.5

Prostate Specific Antigen articles

PSA test helps predicting biopsy need and low risk prostate cancer
The prostate-specific antigen test, commonly known as the PSA test, is valuable in predicting which men should have biopsies and which are likely to be diagnosed with low-risk prostate cancer, a Mayo Clinic study has found. The findings were released during a meeting of the North Central Section of the American Urological Association in Rancho Mirage, California, US.

More aggressive treatment not necessary for men with a family history of prostate cancer
Approximately 10-20 percent of prostate cancer patients have a family history of the disease. There are three major factors that are used to evaluate the extent and aggressiveness of prostate cancer, help make treatment decisions, and estimate prognosis: the Prostate Specific Antigen Level (PSA), Gleason score (GS) from the biopsy, and the digital rectal exam findings (DRE).

New urine test can detect prostate cancer risk early
A new urine test can help aid early detection of and treatment decisions about prostate cancer. Examining the urine sample for TMPRSS2:ERG and PCA3 and stratified patient into low, intermediate and high score, indicating their risk of cancer can help.

Brothers of prostate cancer patients undergo more diagnostic activities
The brothers of men with prostate cancer are at an increased risk of prostate cancer diagnosis because of increased diagnostic activity and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a study published online August 19 in The Journal of the National Cancer Institute.

New PSA test predicts if prostate cancer will return
New research from Northwestern University Feinberg School of Medicine and the University International Institute for Nanotechnology shows that an ultrasensitive PSA test using nanoparticle-based technology (VeriSens™ PSA, Nanosphere, Inc., research-use-only) may be able to definitively predict after surgery if the cancer is cured long term or if it will recur.

Hops compound xanthohumol may prevent prostate cancer
The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer, revealed by US researchers.

Prostate biopsy is not always necessary after raised PSA levels
Elevated prostate specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy, revealed by researchers.

Prostate cancer test age lowered to 40
The age at which men are recommended to first have a test to help identify prostate cancer has been reduced from 50 to 40 years of age.

Prostate cancer screening may result in overdiagnosis of cancer
The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians.

Green tea slows prostate cancer progression
Men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression, revealed by researchers.

Men should get PSA testing at age 40
The American Urological Association (AUA) issued new clinical guidance – which directly contrasts recent recommendations issued by other major groups – about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

PSA screening awareness needed among high-risk groups
In one of the first examinations of PSA screening in younger men, a study published by researchers at Duke Medicine's Prostate Center finds that one-fifth of men under age 50 reported undergoing a prostate specific antigen (PSA) test to detect prostate cancer in the previous year, yet only one in three young black men reported ever having a PSA test in the previous year.

Prostate cancer screening for men over 75 not required
The U.S. Preventive Services Task Force (USPSTF), updating its 2002 report, now recommends against routine prostate cancer screening for men over the age of 75. More evidence is needed to determine if men under 75 could benefit from screening.

Genetic testing can gauge prostate cancer risk
Genetic testing of DNA in a blood sample can determine which men are likely to develop prostate cancer, as five genetic variants previously associated with prostate cancer risk have a strong cumulative effect.

14 Prostate Specific Antigen articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.05